Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

Inclusion Criteria: * Patients with histologically proven advanced head and neck cancer or other solid tumors undergoing radiation therapy * Patients with prior chemotherapy will be considered if chemotherapy occurred more than 30 days prior to this study * Patients must be receiving concomitant radiotherapy (RT) * Performance status of ≥ 70% on the Karnofsky performance scale (KPS) * Must be ≥ 18 years of age * Expected survival of at least three months * Written informed consent Exclusion Criteria: * Patients who meet any of the following clinical laboratory criteria: * Granulocyte count of \< 2000/mm\*\*3 * Platelets \< 75,000/mm\*\*3 * Serum creatinine \> 1.5 times the upper limit of normal * Bilirubin \> 1.5 times the upper limit of normal * Prothrombin time and partial thromboplastin time \> 1.5 times the upper limit of normal * Women who are pregnant * Men and women of child-bearing potential who are unwilling to utilize a medically acceptable method of contraception * Patients who have any known bleeding disorder at the discretion of the investigator * Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependent chronic obstructive pulmonary disease, or unstable liver or renal disease * Treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor or Interleukin-1l within 30 days prior to the start of RT * Patients who have had prior exposure to mitomycin C or porfiromycin